众生药业：全资子公司获得聚乙烯醇化学原料药上市申请批准通知书

Core Viewpoint - Zhongsheng Pharmaceutical (002317) announced that its wholly-owned subsidiary, Guangdong Xianqiang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the raw material drug Polyvinyl Alcohol [1] Company Summary - The approval pertains to the chemical raw material drug Polyvinyl Alcohol, indicating a significant regulatory milestone for the company [1] - This development may enhance the company's product portfolio and market competitiveness in the pharmaceutical industry [1]